Study on Clinical Outcomes of Piperacillin-Tazobactam Extended Infusion in Patients Hospitalised with a Bacterial Infection or Neutropenic Fever

Phase 4

Completed

• Conditions: Infection; Infection - Other infectious diseases

• Registration Number: ACTRN12613001129774
• Lead Sponsor: Fan Sheung Yin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-10
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

Patients were eligible if they were aged 18 years or older; were hospitalized in an acute medical unit or intensive care unit; either had received a diagnosis of bacterial infection or suffered from neutropenic fever; planned to receive treatment of Piperacillin-Tazobactam for at least 48 hours.

Exclusion Criteria

Patients would be excluded if they are pregnant, had received more than 48 hours of effective antibiotics, as defined by specimen culture sensitivity results, within five days of initiation of extended 4-hour infusion or traditional 30-minute infusions of Piperacillin-Tazobactam; had been receiving other beta-lactam antibiotics concomitantly.

Study & Design

• Study Type: Interventional
• Study Design: Not specified